JOURNAL
Current Issue
Journal Archive
 

Chief Editor -
Abdulrazak Abyad MD, MPH, MBA, AGSF, AFCHSE

.........................................................

Publisher -
Lesley Pocock
medi+WORLD International
AUSTRALIA
Email
: lesleypocock@mediworld.com.au
publishermwi@gmail.com
.........................................................

Editorial Enquiries -
abyad@cyberia.net.lb
.........................................................

Advertising Enquiries -
lesleypocock@mediworld.com.au
.........................................................

While all efforts have been made to ensure the accuracy of the information in this journal, opinions expressed are those of the authors and do not necessarily reflect the views of The Publishers, Editor or the Editorial Board. The publishers, Editor and Editorial Board cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; or the views and opinions expressed. Publication of any advertisements does not constitute any endorsement by the Publishers and Editors of the product advertised.

The contents of this journal are copyright. Apart from any fair dealing for purposes of private study, research, criticism or review, as permitted under the Australian Copyright Act, no part of this program may be reproduced without the permission of the publisher.

WFM / MEJFM January/February 2025

Metformin in the treatment of chronic renal disease


Mehmet Rami Helvaci (1), Guner Dede Kurt (2), Hulya Halici (3), Alper Sevinc (1), Celaletdin Camci (1), Abdulrazak Abyad (4), Lesley Pocock (5)

(1) Specialist of Internal Medicine, MD, Turkey
(2) Specialist of Family Medicine, MD, Turkey
(3) Manager of Writing and Statistics, Turkey
(4) Dar Alshifa Hospital Kuwait; Middle-East Academy for Medicine of Aging, MD, Kuwait
(5) medi-WORLD International, Australia

Corresponding author:
Prof Dr Mehmet Rami Helvaci
07400, ALANYA, Turkey
Phone: 00-90-506-4708759
Email: mramihelvaci@hotmail.com

Received: November 2024. Accepted: December 2024; Published: January / February, 2025.Citation: Helvaci MR et al.. Metformin in the treatment of chronic renal disease. World Family Medicine. January/February 2025; 23(1): 12-27. DOI: 10.5742/MEWFM.2025.95257872


Abstract


Background: Atherosclerosis may be the major underlying cause of aging and death.

Methods: All patients with sickle cell diseases (SCD) were included.

Results: We studied 222 males and 212 females with similar ages (30.8 vs 30.3 years, p>0.05, respectively). Smoking (23.8% vs 6.1%, p<0.001), alcohol (4.9% vs 0.4%, p<0.001), transfused red blood cells (RBC) in their lives (48.1 vs 28.5 units, p=0.000), disseminated teeth losses (5.4% vs 1.4%, p<0.001), ileus (7.2% vs 1.4%, p<0.001), chronic renal disease (CRD) (9.9% vs 6.1%, p<0.05), coronary heart disease (18.0% vs 13.2%, p<0.05), cirrhosis (8.1% vs 1.8%, p<0.001), chronic obstructive pulmonary disease (25.2% vs 7.0%, p<0.001), leg ulcers (19.8% vs 7.0%, p<0.001), digital clubbing (14.8% vs 6.6%, p<0.001), and stroke (12.1% vs 7.5%, p<0.05) were all higher in males, significantly.

Conclusion: As a prototype of systemic atherosclerosis, hardened RBC-induced capillary endothelial damage initiating at birth terminates with end-organ failures in much earlier ages in the SCD. Excess fat tissue may be much more important than smoking and alcohol for the development of atherosclerosis and end-organ insufficiencies in human being. The efficacy of metformin in loss of appetite is well known for several years. Since metformin is a safe, cheap, orally used, and effective drug for excess weight, it should be prescribed for the treatment of CRD even in normal weight individuals, since there are nearly 20 kg of excess fat tissue between the upper and lower borders of normal weight in adults.

Key words: Sickle cell diseases, chronic renal disease, excess fat tissue, vascular endothelial inflammation, atherosclerosis, smoking, aging

 





.................................................................................................................

I About MEJFM I Journal I Advertising I Author Info I Editorial Board I Resources I Contact us I Journal Archive I MEPRCN I Noticeboard I News and Updates
Disclaimer - ISSN 148-4196 - © Copyright 2007 medi+WORLD International Pty. Ltd. - All rights reserved